Search clinical trials for: BAY80-6946

Total 498 results

Bayer

Completed

Japanese BAY80-6946 Monotherapy Phase I Study

Neoplasms

Japan
Bayer

Completed

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Lymphoma Non-Hodgkin

Japan
Bayer

Completed

Copanlisib Pharmacodynamic Study

Non Hodgkin Lymphoma

Belgium, France, United Kingdom
Bayer

Completed

Copanlisib Mass Balance Study

Healthy Volunteers

Netherlands
Bayer

Active, not recruiting

A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions

Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Taiwan
Bayer

No longer available

Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors

Cancer

Brazil, Hong Kong, Hungary, Malaysia, Poland, Romania, Russian Federation, Taiwan, Ukraine, Ireland, Chile
Bayer

Completed

Study of Copanlisib in Hepatic or Renal Impairment

Hepatic Insufficiency, Renal Insufficiency

Germany, Romania
Bayer

Completed

Copanlisib Chinese PK Study

Lymphoma, Non-Hodgkin

China
Bayer

Completed

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Neoplasms

United States
Bayer

Completed

Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO)

Advanced or Metastatic Solid Tumor

United States, Spain, Korea, Republic of, Belgium, Singapore, Germany
Bayer

Terminated

Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Lymphoma, Mantle-Cell

United States
Bayer

Completed

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse, Large B-Cell, Lymphoma

Belgium, France, Canada, Korea, Republic of, Australia, Germany, United Kingdom, Italy, Denmark, Singapore
Bayer

Completed

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Lymphoma, Non-Hodgkin

Belgium, France, Spain, Hong Kong, Turkey, Russian Federation, Singapore, United States, Canada, Germany, Australia, New Zealand, Finland, Austria, United Kingdom, Bulgaria, Hungary, Italy, Israel, Korea, Republic of, Poland, Port... and more
Bayer

Completed

Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

Healthy Volunteers

United States
Cancer Trials Ireland

Completed

Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) (Panther)

HER2 Positive Breast Cancer

Ireland
Bayer

Completed

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Neoplasms

United States
Bayer

Active, not recruiting

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-3)

Lymphoma,Non-Hodgkin

China, Hong Kong, Spain, Taiwan, Turkey, Japan, Russian Federation, Singapore, France, Austria, Bulgaria, Korea, Republic of, Malaysia, Thailand, United States, Germany, Hungary, Italy, Philippines, Romania, Poland, Portugal, Mexico, ... and more
NRG Oncology
National Cancer Institute (NCI)

Completed

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Metastatic Endometrioid Adenocarcinoma

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
M.D. Anderson Cancer Center

Withdrawn

BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Bone
Bayer

Completed

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Neoplasms

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

Malignant Solid Neoplasm

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; Bayer

Active, not recruiting

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Colon Cancer | Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer

United States
Bayer

Completed

Phase III Copanlisib in Rituximab-refractory iNHL (CHRONOS-2)

Lymphoma, Non-Hodgkin

Taiwan, Russian Federation, Brazil, Bulgaria, Korea, Republic of, Poland, Italy, Greece, Turkey, South Africa
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Progressive Disease | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | High Grade Ovarian... and other conditions

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Healthy Volunteers | Anemia, Sickle Cell

United States, Spain, Denmark
UNICANCER

Terminated

Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (COPAN-ORL06)

Carcinoma, Squamous Cell of Head and Neck

France
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Richter Syndrome | Indolent Non-Hodgkin Lymphoma

United States
Bayer

Completed

Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis (Phoenix II)

Dermatitis, Atopic

Germany
Columbia University
Bayer

Withdrawn

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Lymphoma, T-Cell
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Myelodysplastic Syndromes

Israel, United States, Korea, Republic of, Australia, France, Germany, Spain, United Kingdom, Czechia, Austria, Italy, Greece, Poland
Bayer

Completed

Gadobutrol Magnevist-controlled Body Study

Magnetic Resonance Imaging

China, Korea, Republic of, Japan
Bayer

Completed

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients

Vascular Diseases

China
Bayer

Completed

A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions

Contrast Enhanced X-ray Based Examination

Germany
Bayer

Terminated

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies

Neoplasms

Germany, United Kingdom, Norway
Life Molecular Imaging SA

Completed

PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.

Diagnostic Imaging

Singapore
Bayer

Completed

Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects

Anemia

Germany
Bayer

Completed

Japanese BAY86-9766 Monotherapy Phase I Study

Neoplasms

Japan
Bayer

Completed

Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)

Anemia

Germany, United Kingdom
National Cancer Institute (NCI)

Withdrawn

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma

United States
Bayer

Completed

Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis

Bronchiectasis

Italy, Spain, Germany, United Kingdom, France
Bayer
Titan Pharmaceuticals

Terminated

Pilot Study of Safety and Efficacy of Spheramine

Parkinson''s Disease

United States
Bayer

Completed

15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific) (DIALOGUE 1)

Renal Insufficiency, Chronic | Anemia

Japan, Korea, Republic of, United Kingdom, Hungary, Israel, Spain, Bulgaria, Australia, Germany, Italy, Poland, Romania, Turkey, France
Bayer

Completed

Age and Gender Effects on the Pharmacokinetics of BAY85-3934

Anemia

United States
Bayer

Recruiting

A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia

Renal Anemia

Japan
Bayer

Completed

Safety of Gadovist in Renally Impaired Patients (GRIP)

Fibrosis | Renal Impairment

Italy, Spain, Korea, Republic of, Germany, Canada, France, Austria, Thailand, Australia, Switzerland
Bayer
Titan Pharmaceuticals

Terminated

STEPS Trial - Spheramine Safety and Efficacy Study

Parkinson Disease

Spain, United States, Germany
Bayer
TAP Pharmaceutical Products Inc.

Completed

Menorrhagia Study in Women With Treatment-resistant Menorrhagia

Menorrhagia
Bayer

Completed

Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Superficial Injuries

Wound Healing | Gene Expression | Cell Proliferation

Germany
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging

Magnetic Resonance Imaging

Japan

Search clinical trials for: BAY80-6946

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations